Loading patent…
AssigneesBristol-Myers Squibb Company, Domantis Limited
InventorsSteven G. Nadler, James K. Tamura, Laura Price, Robert P. Rehfuss, Suzanne J. Suchard, Anish Suri, James William Bryson, Aaron Yamniuk, Steven Grant, Olga Ignatovich, Philip Drew
Estimating the term…
Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.
An isolated antibody polypeptide comprising a first variable domain that specifically binds human CD40L, wherein CD40L comprises the amino acid sequence of SEQ ID NO:
An antibody polypeptide comprising the amino acid sequence of BMS2h-572-633 (SEQ ID NO:
An isolated antibody polypeptide comprising a first variable domain of BMS2h-572 (SEQ ID NO:
An isolated antibody polypeptide comprising a first variable domain selected from the group consisting of the amino acid sequence of BMS2h-572-6 (SEQ ID NO:
A fusion polypeptide comprising SEQ ID NO:
Dependencies are inferred from the claim text.